CMS announced a voluntary test model to allow Medicare Part D plans and state Medicaid programs to cover GLP‑1 drugs prescribed for weight management. The pilot aims to evaluate mechanisms to expand access to GLP‑1s for beneficiaries and could alter payer coverage norms for obesity therapies. The model is a threshold event for U.S. drug access policy: if adopted broadly, it would lower a key barrier that has kept older adults from accessing GLP‑1 treatment under federal programs.